Currently, there are 56.14M common shares owned by the public and among those 54.56M shares have been available to trade.
The company’s stock has a 5-day price change of -6.54% and 16.39% over the past three months. RNST shares are trading 1.84% year to date (YTD), with the 12-month market performance up to 11.84% higher. It has a 12-month low price of $22.99 and touched a high of $37.40 over the same period. RNST has an average intraday trading volume of 249.22K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.24%, 10.10%, and 13.58% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Renasant Corp. (NYSE: RNST) shares accounts for 77.88% of the company’s 56.14M shares outstanding.
It has a market capitalization of $1.93B and a beta (3y monthly) value of 1.04. The stock’s trailing 12-month PE ratio is 13.07, while the earnings-per-share (ttm) stands at $2.62. The company has a PEG of 1.31 and the debt-to-equity ratio at 0.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.87% over the week and 3.57% over the month.
Earnings per share for the fiscal year are expected to increase by 13.33%, and -7.55% over the next financial year. EPS should grow at an annualized rate of 10.00% over the next five years, compared to -1.69% over the past 5-year period.
Looking at the support for the RNST, a number of firms have released research notes about the stock. Hovde Group stated their Market Perform rating for the stock in a research note on July 25, 2024, with the firm’s price target at $36-$38. Raymond James was of a view on October 27, 2022 that the stock is Outperform, while Hovde Group gave the stock Outperform rating on June 21, 2022, issuing a price target of $34. DA Davidson on their part issued Buy rating on February 24, 2022.
